BUSINESS

UCB Japan Gathers Pace in Rare Disease Space with 2 New Launches for gMG

By Sakura Kono November 28, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

UCB Japan is fueling its ambition in the field of rare diseases with the upcoming release of two drugs for generalized myasthenia gravis (gMG). The company aims to make this area the third pillar of its business following “epilepsy” and…

To read the full story

UCB Rolls Out gMG Drug Zilbrysq in Japan
February 19, 2024
Rystiggo Now Available for gMG Patients in Japan: UCB
November 29, 2023

BUSINESS

Teijin to Divest Feburic, Bonalon, Other Legacy Brands to LTL
June 18, 2026
Acumen Exercises Option for Up to Two JCR-Enabled AD Candidates
June 18, 2026
Takeda CEO Pulls in 2.3 Billion Yen in FY2025
June 18, 2026
Sawai’s Revlimid Generic Gains Additional Lymphoma Indications
June 18, 2026
Efient AGs Widen Labels to Close Indication Gap
June 18, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…